{"text": "Potent and stable attenuation of live-HIV-1 by gain of a proteolysis - resistant inhibitor of NF-kappaB ( <extra_id_0> IkappaB-alpha <extra_id_2> Protein <extra_id_1> S32 / 36A ) and the implications for vaccine development .", "event": "<extra_id_0> <extra_id_0> Protein_catabolism proteolysis <extra_id_1> <extra_id_0> Theme IkappaB-alpha <extra_id_1> <extra_id_1>"}
{"text": "Live - attenuated human immunodeficiency viruses ( HIVs ) are candidates for Acquired Immunodeficiency Syndrome ( AIDS ) vaccine .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Based on the simian immunodeficiency virus ( SIV ) model for AIDS , loss - of-function ( e.g . deletion of accessory genes such as <extra_id_0> nef <extra_id_2> Protein <extra_id_1> ) has been forwarded as a primary approach for creating enfeebled , but replication-competent , HIV-1 / SIV .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Regrettably , recent evidence suggests that loss - of-function alone is not always sufficient to prevent the emergence of virulent mutants .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "New strategies that attenuate via mechanisms distinct from loss - of-function are needed for enhancing the safety phenotype of viral genome .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Here , we propose gain-of - function to be used simultaneously with loss - of-function as a novel approach for attenuating HIV-1 .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "We have constructed an HIV-1 genome carrying the cDNA of a proteolysis - resistant nuclear factor-kappaB inhibitor ( <extra_id_0> IkappaB-alpha <extra_id_2> Protein <extra_id_1> S32 / 36A ) in the <extra_id_0> nef <extra_id_2> Protein <extra_id_1> region .", "event": "<extra_id_0> <extra_id_0> Protein_catabolism proteolysis <extra_id_1> <extra_id_0> Theme IkappaB-alpha <extra_id_1> <extra_id_0> Negative_regulation resistant <extra_id_1> <extra_id_0> Theme proteolysis <extra_id_1> <extra_id_1>"}
{"text": "HIV-1 expressing <extra_id_0> IkappaB-alpha <extra_id_2> Protein <extra_id_1> S32 / 36A down-regulates viral expression and is highly attenuated in both Jurkat and peripheral blood mononuclear cells .", "event": "<extra_id_0> <extra_id_0> Gene_expression expressing <extra_id_1> <extra_id_0> Theme IkappaB-alpha <extra_id_1> <extra_id_0> Negative_regulation attenuated <extra_id_1> <extra_id_0> Theme expressing <extra_id_1> <extra_id_1>"}
{"text": "We provide formal proof that the phenotypic and attenuating characteristics of <extra_id_0> IkappaB-alpha <extra_id_2> Protein <extra_id_1> S32 / 36A permit its stable maintenance in a live , replicating HIV-1 despite 180 days of forced ex vivo passaging in tissue culture .", "event": "<extra_id_0> <extra_id_0> Positive_regulation maintenance <extra_id_1> <extra_id_0> Theme IkappaB-alpha <extra_id_1> <extra_id_1>"}
{"text": "As compared with other open-reading frames embedded into HIV / SIV genome , this degree of stability is unprecedented .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Thus , <extra_id_0> IkappaB-alpha <extra_id_2> Protein <extra_id_1> S32 / 36A offers proof-of-principle that artifactually gained functions , when used to attenuate the replication of live HIV-1 , can be stable .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "These findings illustrate gain-of - function as a feasible strategy for developing safer live - attenuated HIVs to be tested as candidates for AIDS vaccine .", "event": "<extra_id_0> <extra_id_1>"}
